Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?

Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.

Andrew Rocco headshot

3 Reasons to Buy Healthcare Stocks in the Current Market Environment

Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.

AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal

Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.

Merck (MRK) Stock Moves -0.04%: What You Should Know

In the latest trading session, Merck (MRK) closed at $108.83, marking a -0.04% move from the previous day.

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.

Merck (MRK), Seagen Drug Combo Gets FDA Nod for Bladder Cancer

The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Merck (MRK) closed at $105.53, marking a -1.31% move from the previous day.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?

Smart Beta ETF report for NULV

Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?

Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Add Novo (NVO) Stock to Your Portfolio

Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.

The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton

Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.

Sheraz Mian headshot

Top Research Reports for Merck, Intel & MercadoLibre

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).

Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.